179 related articles for article (PubMed ID: 37196684)
1. Patient-derived organoids in ovarian cancer: Current research and its clinical relevance.
Kumar S; Raina M; Tankay K; Ingle GM
Biochem Pharmacol; 2023 Jul; 213():115589. PubMed ID: 37196684
[TBL] [Abstract][Full Text] [Related]
2. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity.
Kopper O; de Witte CJ; Lõhmussaar K; Valle-Inclan JE; Hami N; Kester L; Balgobind AV; Korving J; Proost N; Begthel H; van Wijk LM; Revilla SA; Theeuwsen R; van de Ven M; van Roosmalen MJ; Ponsioen B; Ho VWH; Neel BG; Bosse T; Gaarenstroom KN; Vrieling H; Vreeswijk MPG; van Diest PJ; Witteveen PO; Jonges T; Bos JL; van Oudenaarden A; Zweemer RP; Snippert HJG; Kloosterman WP; Clevers H
Nat Med; 2019 May; 25(5):838-849. PubMed ID: 31011202
[TBL] [Abstract][Full Text] [Related]
3. Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine.
Nero C; Vizzielli G; Lorusso D; Cesari E; Daniele G; Loverro M; Scambia G; Sette C
J Exp Clin Cancer Res; 2021 Mar; 40(1):116. PubMed ID: 33789687
[TBL] [Abstract][Full Text] [Related]
4. Protocol for establishing organoids from human ovarian cancer biopsies.
Maenhoudt N; Vankelecom H
STAR Protoc; 2021 Jun; 2(2):100429. PubMed ID: 33870230
[TBL] [Abstract][Full Text] [Related]
5. Patient Derived Organoids (PDOs), Extracellular Matrix (ECM), Tumor Microenvironment (TME) and Drug Screening: State of the Art and Clinical Implications of Ovarian Cancer Organoids in the Era of Precision Medicine.
Spagnol G; Sensi F; De Tommasi O; Marchetti M; Bonaldo G; Xhindoli L; Noventa M; Agostini M; Tozzi R; Saccardi C
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046719
[TBL] [Abstract][Full Text] [Related]
6. Organoids in ovarian cancer: a platform for disease modeling, precision medicine, and drug assessment.
Hu H; Sun C; Chen J; Li Z
J Cancer Res Clin Oncol; 2024 Mar; 150(3):146. PubMed ID: 38509422
[TBL] [Abstract][Full Text] [Related]
7. A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids.
Senkowski W; Gall-Mas L; Falco MM; Li Y; Lavikka K; Kriegbaum MC; Oikkonen J; Bulanova D; Pietras EJ; Voßgröne K; Chen YJ; Erkan EP; Dai J; Lundgren A; Grønning Høg MK; Larsen IM; Lamminen T; Kaipio K; Huvila J; Virtanen A; Engelholm L; Christiansen P; Santoni-Rugiu E; Huhtinen K; Carpén O; Hynninen J; Hautaniemi S; Vähärautio A; Wennerberg K
Dev Cell; 2023 Jun; 58(12):1106-1121.e7. PubMed ID: 37148882
[TBL] [Abstract][Full Text] [Related]
8. Developing Organoids from Ovarian Cancer as Experimental and Preclinical Models.
Maenhoudt N; Defraye C; Boretto M; Jan Z; Heremans R; Boeckx B; Hermans F; Arijs I; Cox B; Van Nieuwenhuysen E; Vergote I; Van Rompuy AS; Lambrechts D; Timmerman D; Vankelecom H
Stem Cell Reports; 2020 Apr; 14(4):717-729. PubMed ID: 32243841
[TBL] [Abstract][Full Text] [Related]
9. An experimental model for ovarian cancer: propagation of ovarian cancer initiating cells and generation of ovarian cancer organoids.
Chen YA; Lu CY; Cheng WF; Kuo KT; Yu CW; Ho HN; Chen HF; Pan SH
BMC Cancer; 2022 Sep; 22(1):967. PubMed ID: 36085021
[TBL] [Abstract][Full Text] [Related]
10. Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testing.
Nanki Y; Chiyoda T; Hirasawa A; Ookubo A; Itoh M; Ueno M; Akahane T; Kameyama K; Yamagami W; Kataoka F; Aoki D
Sci Rep; 2020 Jul; 10(1):12581. PubMed ID: 32724113
[TBL] [Abstract][Full Text] [Related]
11. Current Status of Patient-Derived Ovarian Cancer Models.
Maru Y; Hippo Y
Cells; 2019 May; 8(5):. PubMed ID: 31130643
[TBL] [Abstract][Full Text] [Related]
12. The role of patient-derived ovarian cancer organoids in the study of PARP inhibitors sensitivity and resistance: from genomic analysis to functional testing.
Tao M; Wu X
J Exp Clin Cancer Res; 2021 Oct; 40(1):338. PubMed ID: 34702316
[TBL] [Abstract][Full Text] [Related]
13. Application of Ovarian Cancer Organoids in Precision Medicine: Key Challenges and Current Opportunities.
Yang J; Huang S; Cheng S; Jin Y; Zhang N; Wang Y
Front Cell Dev Biol; 2021; 9():701429. PubMed ID: 34409036
[TBL] [Abstract][Full Text] [Related]
14. Patient-Derived Ovarian Cancer Organoids Mimic Clinical Response and Exhibit Heterogeneous Inter- and Intrapatient Drug Responses.
de Witte CJ; Espejo Valle-Inclan J; Hami N; Lõhmussaar K; Kopper O; Vreuls CPH; Jonges GN; van Diest P; Nguyen L; Clevers H; Kloosterman WP; Cuppen E; Snippert HJG; Zweemer RP; Witteveen PO; Stelloo E
Cell Rep; 2020 Jun; 31(11):107762. PubMed ID: 32553164
[TBL] [Abstract][Full Text] [Related]
15. Patient-derived organoids for precision oncology: a platform to facilitate clinical decision making.
Chitrangi S; Vaity P; Jamdar A; Bhatt S
BMC Cancer; 2023 Jul; 23(1):689. PubMed ID: 37479967
[TBL] [Abstract][Full Text] [Related]
16. Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors.
Maru Y; Tanaka N; Itami M; Hippo Y
Gynecol Oncol; 2019 Jul; 154(1):189-198. PubMed ID: 31101504
[TBL] [Abstract][Full Text] [Related]
17. Patient-Derived Organoids: The Beginning of a New Era in Ovarian Cancer Disease Modeling and Drug Sensitivity Testing.
Psilopatis I; Sykaras AG; Mandrakis G; Vrettou K; Theocharis S
Biomedicines; 2022 Dec; 11(1):. PubMed ID: 36672509
[TBL] [Abstract][Full Text] [Related]
18. Integration of Genomic Profiling and Organoid Development in Precision Oncology.
Yoon H; Lee S
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008642
[TBL] [Abstract][Full Text] [Related]
19. Long non-coding RNAs in recurrent ovarian cancer: Theranostic perspectives.
Bhardwaj V; Tan YQ; Wu MM; Ma L; Zhu T; Lobie PE; Pandey V
Cancer Lett; 2021 Apr; 502():97-107. PubMed ID: 33429007
[TBL] [Abstract][Full Text] [Related]
20. Progress and perspective of organoid technology in cancer-related translational medicine.
Lin Y; Jiang L; He Q; Yuan M; Cao J
Biomed Pharmacother; 2022 May; 149():112869. PubMed ID: 35358798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
